The combined effects of anti-TNFα antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane

Cytokine

Volumn 32, Issue 6, 2005, Pages 263-269

  Hosaka, Kunihiro ^a   Ryu, Junnosuke ^a   Saitoh, Shu ^a   Ishii, Takao ^a   Kuroda, Kazumichi ^a   Shimizu, Kazufumi ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Anti TNF antibody; Combination; IL 1 receptor antagonist; Rheumatoid arthritis; Synovial membrane

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EX VIVO STUDY; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 31744435495     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2005.11.005     Document Type: Article

References (36)

1. F.M. Brennan, M. Field, C.Q. Chu, M. Feldmann, and R.N. Maini Cytokine expression in rheumatoid arthritis Br J Rheumatol 30 Suppl. 1 1991 76 80
2. E.H. Choy, and G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 2001 907 916
3. J.M. Dayer Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis? J Rheumatol Suppl 65 2002 10 15
4. P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 343 2000 1594 1602
5. S. Cohen, E. Hurd, J. Cush, M. Schiff, M.E. Weinblatt, and L.W. Moreland Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 2002 614 624
6. U. Feige, Y.L. Hu, J. Gasser, G. Campagnuolo, L. Munyakazi, and B. Bolon Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats Cell Mol Life Sci 57 2000 1457 1470
7. A.M. Bendele, E.S. Chlipala, J. Scherrer, J. Frazier, G. Sennello, and W.J. Rich Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis Arthritis Rheum 43 2000 2648 2659
8. J.H. Schwab, R.R. Brown, S.K. Anderle, and P.M. Schlievert Superantigen can reactivate bacterial cell wall-induced arthritis J Immunol 150 1993 4151 4159
9. S.H. Kim, E.R. Lechman, S. Kim, J. Nash, T.J. Oligino, and P.D. Robbins Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis Mol Ther 6 2002 591 600
10. J. Zwerina, S. Hayer, M. Tohidast-Akrad, H. Bergmeister, K. Redlich, and U. Feige Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction Arthritis Rheum 50 2004 277 290
11. M. Chabaud, and P. Miossec The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model Arthritis Rheum 44 2001 1293 1303
12. F.C. Arnett, S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, and N.S. Cooper The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 1988 315 324
13. H. Ounissi-Benkalha, J.P. Pelletier, G. Tardif, F. Mineau, F.C. Jolicoeur, and P. Ranger In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis J Rheumatol 23 1996 16 23
14. P. Seckinger, J. Klein-Nulend, C. Alander, R.C. Thompson, J.M. Dayer, and L.G. Raisz Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production J Immunol 145 1990 4181 4184
15. G. Kim, J.B. Jun, and K.B. Elkon Necessary role of phosphatidylinositol 3-kinase in transforming growth factor beta-mediated activation of Akt in normal and rheumatoid arthritis synovial fibroblasts Arthritis Rheum 46 2002 1504 1511
16. M. Suzuki, T. Tetsuka, S. Yoshida, N. Watanabe, M. Kobayashi, and N. Matsui The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts FEBS Lett 465 2000 23 27
17. A.I. Catrina, J. Lampa, S. Ernestam, E. af Klint, J. Bratt, and L. Klareskog Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis Rheumatology (Oxford) 41 2002 484 489
18. J.G. Jeong, J.M. Kim, H. Cho, W. Hahn, S.S. Yu, and S. Kim Effects of IL-1beta on gene expression in human rheumatoid synovial fibroblasts Biochem Biophys Res Commun 324 2004 3 7
19. S.R. Goldring Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol Suppl 65 2002 44 48
20. J.M. Dayer The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis Rheumatology (Oxford) 42 Suppl. 2 2003 ii3 ii10
21. D.J. Shealy, P.H. Wooley, E. Emmell, A. Volk, A. Rosenberg, and G. Treacy Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice Arthritis Res 4 5 2002 R7 [Epub 2002 Jun 28]
22. S.C. Ghivizzani, R. Kang, H.I. Georgescu, E.R. Lechman, D. Jaffurs, and J.M. Engle Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis J Immunol 159 1997 3604 3612
23. A.K. Ulfgren, U. Andersson, M. Engstrom, L. Klareskog, R.N. Maini, and P.C. Taylor Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis Arthritis Rheum 43 2000 2391 2396
24. F.M. Brennan, D. Chantry, A. Jackson, R. Maini, and M. Feldmann Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis Lancet 2 1989 244 247
25. R.O. Williams, L. Marinova-Mutafchieva, M. Feldmann, and R.N. Maini Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy J Immunol 165 2000 7240 7245
26. P. Isler, E. Vey, J.H. Zhang, and J.M. Dayer Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69 Eur Cytokine Netw 4 1993 15 23
27. M. Harigai, M. Hara, A. Kitani, K. Norioka, T. Hirose, and W. Hirose Interleukin 1 and tumor necrosis factor-alpha synergistically increase the production of interleukin 6 in human synovial fibroblast J Clin Lab Immunol 34 1991 107 113
28. K.L. MacNaul, N. Chartrain, M. Lark, M.J. Tocci, and N.I. Hutchinson Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression J Biol Chem 265 1990 17238 17245
29. F. Berenbaum, C. Jacques, G. Thomas, M.T. Corvol, G. Bereziat, and J. Masliah Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on PGE2 production by articular chondrocytes does not involve PLA2 stimulation Exp Cell Res 222 1996 379 384
30. P. Rathanaswami, M. Hachicha, W.L. Wong, T.J. Schall, and S.R. McColl Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on interleukin-8 gene expression in synovial fibroblasts. Evidence that interleukin-8 is the major neutrophil-activating chemokine released in response to monokine activation Arthritis Rheum 36 1993 1295 1304
31. J. Kay, and L. Calabrese The role of interleukin-1 in the pathogenesis of rheumatoid arthritis Rheumatology (Oxford) 43 Suppl. 3 2004 iii2 iii9
32. L.A. Joosten, M.M. Helsen, F.A. van de Loo, and W.B. van den Berg Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra Arthritis Rheum 39 1996 797 809
33. P. Charles, M.J. Elliott, D. Davis, A. Potter, J.R. Kalden, and C. Antoni Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis J Immunol 163 1999 1521 1528
34. J.N. Gouze, E. Gouze, G.D. Palmer, V.S. Liew, A. Pascher, and O.B. Betz Comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer Arthritis Res Ther 5 2003 R301 R309 [Epub 2003 Aug 1]
35. M.H. Buch, S.J. Bingham, Y. Seto, D. McGonagle, V. Bejarano, and J. White Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade Arthritis Rheum 50 2004 725 728
36. M.C. Genovese, S. Cohen, L. Moreland, D. Lium, S. Robbins, and R. Newmark Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Arthritis Rheum 50 2004 1412 1419